PriceSensitive

Optimi Health (CSE:OPTI) finalizes supply agreement with ATMA

Consumer
CSE:OPTI
08 June 2022 12:30 (EDT)

Optimi Health (OPTI) has entered into an exploratory supply agreement with ATMA to supply psilocybin products.

ATMA Journey Centers is a privately held facilitator of psilocybin-assisted therapy and practitioner training services for palliative care and mental health conditions. It is based in Calgary, Alberta.

Bill Ciprick, CEO of Optimi Health commented on the news.

“Optimi is deeply gratified to provide ATMA with this test supply of natural psilocybin in order to facilitate research. The research may lead to better mental health services for healthcare workers while testing the potential to expand the scale of available psilocybin therapies.”

Optimi Health is looking forward to opportunities presented by this partnership with ATMA. The company is keen on advancing the knowledge base of trained psychedelic therapists by providing learning experiences and real-world data derived from the direct administration of a natural psilocybin product.

The company views this as an opportunity to refine approaches and improve efficiencies around the commercial distribution and clinical applications of psilocybin. It anticipates more robust demand as clinical research improves regulatory outcomes for psychedelic medicine.

Optimi Health engages in producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms that focus on the health and wellness markets. With a vertically integrated approach, Optimi cultivates, extracts, processes and distributes high quality functional and psychedelic mushroom products at its two facilities in Princeton, British Columbia.

Optimi Health Corp. (OPTI) was down 1.67 per cent, trading at C$0.295 per share at 12:02 pm ET.

Related News